Kisqali®

Active substance

Ribociclib

Holder

Novartis

Status

Closed

Indication

In combination with letrozole for adult postmenopausal women as initial endocrine-based therapy for hormone receptor-positive (HR+) HER2-negative (HER2-) locally advanced or metastatic breast cancer.

Documents publics

Approbation

Information for the patient

Informed consent

Dernière mise à jour

17/01/2018
Last updated on 13/02/2024